3 items2 sources1 stocks
The Motley Fool-Oct 29, 06:23 PM
NovoCure (NVCR) Q3 2026 Earnings Call Transcript
NovoCure (NVCR) Q3 2026 Earnings Call Transcript(摘要待生成)
The Motley Fool-Nov 10, 06:50 PM
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.(摘要待生成)
NVCRhealthcare
Novocure investor relations-Nov 9, 12:00 PM
Novocure receives FDA “Not Approvable” letter for Optune Mya brain-metastases application
On November 9, 2026, Novocure said FDA declined its PMA application for Optune Mya in adults with NSCLC brain metastases following stereotactic radiation, citing uncertainty about clinical benefit, not safety. The company said it plans to meet with FDA. This is relevant sector regulatory news, not an Alpha Tau action.
NVCRregulatory_action